Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.47
- Piotroski Score 3.00
- Grade Buy
- Symbol (IPSC)
- Company Century Therapeutics, Inc.
- Price $1.58
- Changes Percentage (2.27%)
- Change $0.04
- Day Low $1.48
- Day High $1.59
- Year High $5.51
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $27.00
- Low Stock Price Target $9.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.22
- Trailing P/E Ratio -1.32
- Forward P/E Ratio -1.32
- P/E Growth -1.32
- Net Income $-136,673,000
Income Statement
Quarterly
Annual
Latest News of IPSC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Klipsch Launches World's First PS5 And Xbox Series X-Friendly Soundbar With Dirac Room Correction
The Klipsch Flexus Core 300 soundbar, equipped with Dirac Live Room Correction Technology, offers premium sound quality with a 5.1.2 channel configuration and compatibility with DTS:X and Dolby Atmos....
By Forbes | 1 week ago -
After losing 17% in the past year, Century Therapeutics, Inc. (NASDAQ:IPSC) institutional owners must be relieved by the recent gain
Institutions owning a substantial 29% stake in Century Therapeutics (NASDAQ:IPSC) indicates their significant influence on the company's share price. Institutional investors closely watch the company'...
By Yahoo! Finance | 1 month ago
